Thumbnail Image
Publication

Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis

Abdelhameed, Farah
; 
Lagojda, Lukasz
; 
Kite, Chris
; 
Dallaway, Alexander
; 
Mustafa, Attia
; 
Than, Nwe Ni
; 
Kassi, Eva
; 
Randeva, Harpal S.
; 
Kyrou, Ioannis
Advisors
Editors
Other Contributors
Affiliation
University Hospitals Coventry and Warwickshire NHS Trust; University of Sheffield; University of Wolverhampton; University of Chester; University of Warwick; Omar Almukhtar University; University of Buckingham; National and Kapodistrian University of Athens; Coventry University; Aston University; University of Derby; Agricultural University of Athens
EPub Date
Publication Date
2025-04-10
Submitted Date
Collections
Chester Medical School
Show all metadata
Files
Thumbnail Image
Article - VoR
Adobe PDF, 6.33 MB
Other Titles
Abstract
Background: Steatotic liver disease related to metabolic dysfunction is the most common cause of chronic liver disease globally. The spectrum of this condition includes steatosis and steatohepatitis and was previously referred to as non-alcoholic fatty liver disease (NAFLD) but has been renamed as metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently as metabolic dysfunction-associated steatotic liver disease (MASLD). Angiopoietin-like protein 8 (ANGPTL8), also known as betatrophin or lipasin, regulates triglycerides and has emerged as a potential novel biomarker for steatosis/steatohepatitis. Therefore, this systematic review aimed to identify and synthesize the evidence on the possible association of circulating ANGPTL8 concentrations with NAFLD, MAFLD or MASLD. Methods: PubMed/MEDLINE, Cochrane Library, EMBASE, and Web of Science were searched for studies published in English reporting circulating ANGPTL8 concentrations in adults with NAFLD or MAFLD or MASLD and controls. A meta-analysis was performed, reporting the standardized mean difference (SMD) of circulating ANGPTL8 concentrations between these two groups. Study quality and risk of bias were assessed using the NIH quality assessment tool and RoBANS 2, respectively. Results: Of the 104 identified publications, eight studies were eligible for this systematic review, whilst seven were also eligible for meta-analysis (543 NAFLD or MAFLD cases vs. 352 controls). Circulating ANGPTL8 concentrations were significantly higher in patients with NAFLD or MAFLD compared with controls (SMD: 0.62, 95%CI: 0.28-0.97; p<0.001). Considerable heterogeneity was noted among these studies, with six studies having high risk of bias in at least one RoBANS 2 domain. Conclusion: These findings present up-to-date comprehensive evidence indicating that adults with steatotic liver disease related to metabolic dysfunction exhibit higher circulating ANGPTL8 concentrations compared with controls. Given the need for novel screening/diagnostic biomarkers for steatosis/steatohepatitis, as well for additional drug targets, large and prospective studies are required to confirm this association and explore its temporal direction, particularly under the new MASLD diagnosis/term.
Citation
Abdelhameed, F., Lagojda, L., Kite, C., Dallaway, A., Mustafa, A., Than, N. N., Kassi, E., Randeva, H. S., & Kyrou, I. (2025). Circulating angiopoietin-like protein 8 (ANGPTL8) and steatotic liver disease related to metabolic dysfunction: an updated systematic review and meta-analysis. Frontiers in Endocrinology, 6:1574842. https://doi.org/10.3389/fendo.2025.1574842
Publisher
Frontiers Media
Journal
Frontiers in Endocrinology
Research Unit
URI
http://hdl.handle.net/10034/629377
DOI
10.3389/fendo.2025.1574842
PubMed ID
PubMed Central ID
Type
Article
Language
Description
Series/Report no.
ISSN
1664-2392
EISSN
1664-2392
ISBN
ISMN
Gov't Doc
Test Link
Sponsors
N/A
Additional Links
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1574842/full